Federal drug scheduling usually works categorically: a plant or compound goes on a schedule, in full. The government’s move against kratom’s most potent alkaloid does something more surgical, and more consequential for exactly that reason. The DEA has filed notice of intent to temporarily place 7-hydroxymitragynine, or 7-OH, into Schedule I, but only above a specific concentration threshold, while stating explicitly that ordinary botanical kratom leaf is not the target. A 30-day public comment period, open through July 31, will shape where that numeric line actually falls, and how it gets measured, which will determine how much of the current kratom market ends up scheduled and how much does not.

The substance and the split it’s built on

Kratom is the botanical product of Mitragyna speciosa, a Southeast Asian tree, and its two most-discussed alkaloids are mitragynine and 7-hydroxymitragynine. 7-OH occurs in the raw leaf only in trace amounts, but it is significantly more potent at opioid receptors than mitragynine, and it is the compound found concentrated, sometimes dramatically, in extracts, shots, gummies, and tablets sold in gas stations, convenience stores, and smoke shops. HHS’s own pharmacovigilance data shows why regulators are moving now: adverse-event reports tied to 7-OH in the FDA’s surveillance database rose from a handful of cases in 2023 and 2024 to 86 cumulative cases by early 2026, the substantial majority classified as serious and nine resulting in death, alongside 85 cases identified in DEA’s forensic toxicology program since 2019, 55 of them fatal.

The government’s chosen mechanism is a threshold, not a ban on the plant. The DEA’s proposed line is roughly 0.05 percent 7-OH by weight in botanical material, or the equivalent concentration in processed products, with a floor of one milligram of 7-OH in a single article. Products above that line would become Schedule I. Natural leaf kratom below it would not be touched. Alongside the 7-OH threshold, a second, separate action would place three synthetic 7-OH derivatives, compounds that do not occur naturally in the plant at all, directly into Schedule I outright.

What the comment period actually decides

This is where the story becomes an active rather than a settled one. HHS’s Office of the Assistant Secretary for Health has opened a formal request for information asking specifically whether the proposed threshold level is right, whether the science supports a different cutoff, and whether concentration should even be the right way to measure the line, as opposed to an absolute milligram quantity or some other metric. Those are not rhetorical questions. Federal reporting already shows commercial 7-OH products on the market today ranging enormously in dose, from roughly 1 milligram to 700 milligrams per serving. Depending on where the final threshold and its unit of measurement land, that range of products could end up almost entirely swept into Schedule I, or only its most concentrated tail. The comment period is the actual policymaking moment; the notice of intent describes the government’s opening position, not its final one.

Why the mechanism matters as much as the substance

A concentration-based, botanical-versus-synthetic threshold is a notably different regulatory instrument than the categorical Schedule I designation applied to most controlled substances, and other quarters of the market appear to read it as a template. The DEA’s own filing states that HHS found no approved or investigational new drug applications for 7-OH, meaning there is currently no pharmaceutical pathway relying on the compound that this action would disrupt, which is one reason the threshold approach is politically and legally simpler to execute now than it would be for a compound already in development. But the approach itself, distinguishing a natural botanical from its synthetically concentrated derivatives by a measurable potency line rather than banning the source plant outright, is a live regulatory model that other borderline botanical and cannabinoid products are likely to be compared against as their own concentration and potency questions come up.

The caveats

This is a temporary scheduling action, not a permanent one; the Controlled Substances Act allows the Attorney General to schedule a substance for up to two years to address an imminent public safety hazard while a fuller review proceeds, so this is an emergency measure with a defined shelf life, not final law. Nothing is scheduled yet: the notices of intent describe an intended action, the comment period runs through July 31, and only after comments are reviewed and at least thirty days pass can a temporary order actually issue. Federal action has not preempted the states, several of which, including Tennessee as of this month, already restrict 7-OH under their own kratom statutes, so the regulatory landscape remains a patchwork regardless of what the federal threshold ultimately says. And the industry response so far has been notably cooperative rather than adversarial: an established botanical-research advocacy group has publicly welcomed the distinction between concentrated synthetic derivatives and natural leaf, suggesting less immediate legal resistance than categorical scheduling actions typically provoke, though that could shift once the specific threshold numbers are finalized and their market impact becomes concrete.

The frame

The kratom-as-opioid debate has run for years as a binary argument, ban it or leave it alone. This action steps around that binary entirely, and the choice of instrument is the real news. By regulating potency rather than the plant, the government is betting it can suppress the products driving the adverse-event data without eliminating the wider market some states have chosen to preserve. Whether that bet succeeds depends entirely on where the line gets drawn, and the public comment window closing July 31 is the mechanism by which industry, harm-reduction advocates, and public health researchers can still move that line. For a substance sitting at the messy edge of natural product, dietary supplement, and unscheduled opioid-like compound, a threshold is a genuinely different kind of regulatory tool than this desk has tracked in cannabis or psychedelics policy, and it is worth watching as a possible template for how difficult-to-categorize botanical compounds get regulated going forward.